| Overview |
| bs-12462R-Biotin |
| AGPS/Alkyl-DHAP synthase Antibody, Biotin Conjugated |
| ELISA, IHC-P, IHC-F |
| Rat |
| Human, Mouse, Cow, Pig, Horse |
| Specifications |
| Biotin |
| Rabbit |
| KLH conjugated synthetic peptide derived from human AGPS/Alkyl-DHAP synthase |
| 31-130/658 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C for 12 months. |
| Target |
| 8540 |
| Cytoplasm, Cell membrane |
| AAG5; ADAP-S; ADAS; ADAS_HUMAN; ADHAPS; ADPS; Aging associated gene 5 protein; Aging-associated gene 5 protein; AGPS; ALDHPSY; Alkyl-DHAP synthase; Alkyldihydroxyacetonephosphate synthase; Alkyldihydroxyacetonephosphate synthase, peroxisomal; Alkylglycerone phosphate synthase; Alkylglycerone-phosphate synthase; peroxisomal. |
| AGPS is a 658 amino acid enzyme that is required for glycerolipid metabolism and ether lipid biosynthesis. Localized to the inner aspect of the peroxisomal membrane, AGPS is likely part of a heterotrimeric complex that is also composed of GNPAT and a modified form of GNPAT. Containing one FAD-binding PCMH-type domain, AGPS utilizes FAD as a cofactor in the synthesis of alkyl-glycerone 3-phophate and a long-chain acid anion from 1-acteyl-glyerone 3-phosphate and a long-chain alcohol. Defects in the gene encoding AGPS results in rhizomelic chondrodysplasia punctata type 3, a disease characterized by vertebral disorders, severe mental retardation, cutaneous lesions, cataracts and rhizomelic shortening of the humerus and femur. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz